Molecular Characterization and Antimicrobial Susceptibility Study of Acinetobacter baumannii Clinical Isolates from Middle East, African and Indian Patients
Manu Chaudhary and Anurag Payasi*
Department of Cell Culture and Molecular Biology, Venus Medicine Research Centre, Baddi, Himachal Pradesh, India
- *Corresponding Author:
- Anurag Payasi
Venus Medicine Research Centre
Hill Top Industrial Estate
Bhatoli Kalan, Baddi, H.P. - 173205 India
E-mail: [email protected]
Received Date: October 29, 2012; Accepted Date: November 15, 2012; Published Date: November 19, 2012
Citation: Chaudhary M, Payasi A (2012) Molecular Characterization and Antimicrobial Susceptibility Study of Acinetobacter baumannii Clinical Isolates from Middle East, African and Indian Patients J Proteomics Bioinform 5: 265-269. doi: 10.4172/jpb.1000248
Copyright: © 2012 Chaudhary M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The aim of the present investigation was to characterize the prevalence of extended-spectrum β-lactamases (ESBLs) and metallo β-lactamases (MBLs), and to study the antibiotic susceptibility profile among 250 clinical isolates of Acinetobacter baumannii. Phenotypic characterization was carried out by double disc synergy method and the prevalence of ESBLs and MBLs antibiotic resistant determinants were analyzed with Polymerase Chain Reaction (PCR). Susceptibility studies were performed by disc diffusion method according to Clinical and Laboratory Standards Institute guidelines 2009.
Among the two hundred fifty isolates, two hundred nine isolates (83.6%) were positive for ESBLs whereas one hundred sixty seven isolates (79.9%) were positive for both ESBLs and MBLs. Moreover, five isolates (2.3%) which were positive for MBL on disc diffusion test, but negative in PCR showed MBL activity by spectrophotometric assay. Susceptibility study showed that all of the isolates were found to be more susceptible to ceftriaxone plus ethylenediaminetetraacetate plus sulbactam (90-93%), followed by meropenem (50-53%), imipenem (42-45%), cefoperazone plus sulbactam (40-42%), piperacillin plus tazobactam (38-42%) and amoxicillin plus clavulanic acid (28-31%). Among the ESBLs, TEM-types were varied from 82 to 87% followed by SHV-types (67-78%), CTX-M types (60 to 67) and OXA types (51 to 56%) in all of the isolates. Among the MBLs, NDM-1 varied from 40 to 49% followed by IMP-1 (51 to 55%), VIM-1 (55 to 59%) and KPC (47 to 55%) in all of the isolates. Moreover, results of the present study revealed that all of the clinical isolates were susceptible to ceftriaxone plus EDTA plus sulbactam and can be a potent antibacterial agent for the treatment of severe bacterial infections caused by A. baumannii.